Two Cases of Heparin-Induced Thrombocytopenia in Hemodialysis Patients.
- Author:
Hee Jeong CHOI
1
;
Duk Hyun LEE
;
Young Deuk YOUN
;
Sung Ho KIM
;
Jung Ahn RHEE
;
Soon Hee CHANG
;
Jang Soo SUH
Author Information
1. Department of Internal Medicine, Daegu Fatima Hospital, Korea. dhlee@fatima.or.kr
- Publication Type:Case Report
- Keywords:
Heparin-induced thrombocytopenia;
Hemodialysis;
Anticoagulant
- MeSH:
Arteriovenous Fistula;
Heparin;
Humans;
Mesylates;
Mortality;
Renal Dialysis*;
Thrombocytopenia*;
Venous Thromboembolism
- From:Korean Journal of Nephrology
2006;25(1):135-140
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Heparin, a widely used anticoagulant, is currently the anticoagulant of choice in long-term hemodialysis (HD). Heparin-induced thrombocytopenia (HIT) is one of the most serious side effects of heparin which can cause arterial or venous thromboembolism associated with substantial morbidity and mortality. We experienced two patients who had thrombocytopenia and vascular access occlusion during the induction period of HD with the use of unfractionated heparin. Thrombocytopenia was improved after discontinuation of heparin. HIT was confirmed with anti-heparin/platelet factor 4 antibody test. HD was conducted and arteriovenous fistula was created successfully after switch of heparin to argatroban (Novastan(R)) or nafamostat mesilate (Futhan(R)). Nephrologist should rule out HIT first when thrombocytopenia and thromboembolic complications occur after use of heparin, especially during the induction period of HD. For suspicious patients, immediate cessation of heparin and switch to alternative anticoagulant is very important to avoid serious complications.
